Search
EyePoint Pharmaceuticals Inc
EYPTAdd to Watchlist
13.980USD
+0.785+5.95%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.95%
5 Days
-2.92%
1 Month
+6.31%
6 Months
-23.48%
Year to Date
-23.48%
1 Year
+46.39%
Key Figures
13.200Open
14.190High
1.49MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.80%Turnover Ratio
13.195Prev. Close
13.050Low
15.04MTurnover
LossP/E Static
3.78P/B
0.00%Div Yield TTM
-83.47%ROA
19.11052wk High
1.28Volume Ratio
-130.87MNet Profit
82.83MShares
-3.5053EPS TTM
1.74Beta
-102.71%ROE
6.85052wk Low
8.64%Amplitude
24.14%Gross Margin
1.16BMarket Cap
1.66Reward/Risk
4.17%Risk Rate
TradingKey Stock Score of EyePoint Pharmaceuticals Inc
Currency: USD Updated: 2026-07-01Key Insights
EyePoint Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 75 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.00.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
EyePoint Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
EyePoint Pharmaceuticals Inc Highlights
StrengthsRisks
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Growing
The company is in a growing phase, with the latest annual income totaling USD 31.37M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 31.37M.
Fairly Valued
The company’s latest PE is -3.76, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 88.53M shares, decreasing 3.02% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 81.31K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.30.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
37.000
Target Price
+158.74%
Upside Space
EyePoint Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
EyePoint Pharmaceuticals Inc Info
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Ticker SymbolEYPT
CompanyEyePoint Pharmaceuticals Inc
CEODuker (Jay S)
Websitehttps://eyepointpharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52827.700
+573.400 (+1.10%)
29314.600
-484.700 (-1.63%)
7469.400
-6.100 (-0.08%)
14799.000
-556.000 (-3.62%)
68146.000
-1339.000 (-1.93%)
6351.400
+76.000 (+1.21%)
68.344
+0.376 (+0.55%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4121.000
+90.230 (+2.24%)
FAQs
What is the current price of EyePoint Pharmaceuticals Inc (EYPT)?
The current price of EyePoint Pharmaceuticals Inc (EYPT) is 13.20.
What is the symbol of EyePoint Pharmaceuticals Inc?
The ticker symbol of EyePoint Pharmaceuticals Inc is EYPT.
What is the 52-week high of EyePoint Pharmaceuticals Inc?
The 52-week high of EyePoint Pharmaceuticals Inc is 19.11.
What is the 52-week low of EyePoint Pharmaceuticals Inc?
The 52-week low of EyePoint Pharmaceuticals Inc is 6.85.
What is the market capitalization of EyePoint Pharmaceuticals Inc?
The market capitalization of EyePoint Pharmaceuticals Inc is 1.11B.
Is EyePoint Pharmaceuticals Inc (EYPT) currently rated as Buy, Hold, or Sell?
According to analysts, EyePoint Pharmaceuticals Inc (EYPT) has an overall rating of Buy, with a price target of 37.00.
What is the Earnings Per Share (EPS TTM) of EyePoint Pharmaceuticals Inc (EYPT)?
The Earnings Per Share (EPS TTM) of EyePoint Pharmaceuticals Inc (EYPT) is -3.17.